Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2005 2
2006 2
2007 2
2010 1
2011 1
2012 1
2013 1
2014 1
2015 4
2016 3
2017 2
2018 3
2020 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Cloughesy TF, et al. Among authors: ostertag d. JAMA Oncol. 2020 Dec 1;6(12):1939-1946. doi: 10.1001/jamaoncol.2020.3161. JAMA Oncol. 2020. PMID: 33119048 Free PMC article. Clinical Trial.
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T. Cloughesy TF, et al. Among authors: ostertag d. Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075. Neuro Oncol. 2018. PMID: 29762717 Free PMC article. Clinical Trial.
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Accomando WP, Rao AR, Hogan DJ, Newman AM, Nakao A, Alizadeh AA, Diehn M, Diago OR, Gammon D, Haghighi A, Gruber HE, Jolly DJ, Ostertag D. Accomando WP, et al. Among authors: ostertag d. Clin Cancer Res. 2020 Dec 1;26(23):6176-6186. doi: 10.1158/1078-0432.CCR-20-0536. Epub 2020 Aug 18. Clin Cancer Res. 2020. PMID: 32816892 Free article. Clinical Trial.
Organ-specific Neurodegeneration in Triple A syndrome-related Achalasia.
Zimmer V, Vanderwinden JM, Zimmer A, Ostertag D, Strittmatter M, Koehler K, Huebner A, Lammert F. Zimmer V, et al. Among authors: ostertag d. Am J Med. 2015 Sep;128(9):e9-12. doi: 10.1016/j.amjmed.2015.04.025. Epub 2015 May 23. Am J Med. 2015. PMID: 26007668 No abstract available.
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA. Cloughesy TF, et al. Among authors: ostertag d. Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784. Sci Transl Med. 2016. PMID: 27252174 Free PMC article. Clinical Trial.
24 results